Atom Bioscience planning phase III gout trial after encouraging mid-stage readout - BioWorld Online

Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd., a company developing an oral a urate anion exchanger 1 inhibitor for the potential treatment of chronic gout, said results of a phase IIa trial show that its lead candidate, ABP-671, reduced serum uric acid levels to less than 6 mg/dL, below the clinically defined threshold of 7 mg/dL for hyperuricemia, or excess of uric acid in the blood, which leads to gout.

BioWorld Clinical Inflammatory China

Adblock test (Why?)

Comments

Popular posts from this blog

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more

How to perform chest auscultation and interpret the findings - Nursing Times

“National Day Awards 2019, Singapore News & Top Stories - The Straits Times” plus 1 more